Mode
Text Size
Log in / Sign up
N/A N=80 Randomized Triple-blind Treatment

Assessment of Three Basic Progressive Lens Designs

Presbyopia

Enrolled (actual)
80
Serious AEs
0.0%
Results posted
Aug 2024
Primary outcome: Primary: Evaluate the Adaptation to Progressive Lens Designs. — 4.125; 4.025; 3.875; 3.725 score on a scale

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
Progressive Additional Lenses (PAL), pre calibrated and made of polymeric material with anti-reflection coating (Device)
Age
Adult, Older Adult · 45+ yrs
Sex
All
Sponsor
Western University of Health Sciences
Primary completion
Jun 2022

Outcome Measures

OutcomeResultp-value
PRIMARY
Evaluate the Adaptation to Progressive Lens Designs.
4.125; 4.025; 3.875; 3.725; 4.300; 4.150
SECONDARY
Evaluate the Immediate Preference Among Progressive Lens Designs.
4.550; 4.400; 4.625; 4.450; 4.625; 4.400
SECONDARY
Evaluate the Preference of Progressive Lens Designs.
11; 16; 10; 9; 19; 15

Summary

This clinical trial investigates the differences between three different progressive addition lens designs. It is a non-invasive double-masked randomized clinical investigation. For this study, 80 participants will be recruited.

Eligibility Criteria

Inclusion Criteria

  • Age: 45 to 70 years old.
  • Visual Acuity: far & near monocular: cc ≥ 20/20 (decimal cc ≥ 1.0)
  • Normal binocular vision (at distance & near: no strabismus on cover testing, aligning prism of less than 2Δ horizontally or vertically, stereoacuity of 2' or better at distance and near).
  • Prescription is in the range:
  • Spherical power: less than +/-6.00 D
  • Cylindrical power: less than -2.75 D
  • Addition: 1.50 D - 2.50 D
  • Difference in power (spherical equivalent) between eyes: less than 2.00 D

Exclusion Criteria

  • Have never worn any progressive lens design.
  • First prescription for progressive lenses.
  • Prescription found during visit#1 varies from current prescription more than 0.50 D in any meridian.
  • Currently wearing single vision lenses with accommodative support.
  • Double vision or prismatic prescription in current glasses.
  • Known ocular disease including strabismus, any pathology, any eye surgeries that may affect visual acuity.
  • Use of systemic or ocular medications that are likely to affect vision.
  • Balance problem/vertigo problem.
  • Concurrent participation in other vision-related research.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT05252871). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search